Objective: The present study, for the first time, was designed to examine the antifibrosis effects of Shenge Yangfei Capsules (SGYF) on bleomycin-induced pulmonary injury and fibrosis in rats. Methods: Animals were divided into six groups randomly: saline control group, bleomycin group, and SGYC (70, 420 or 850 mg/kg/d, ig) group, and positive control group. Animals were sacrificed on day of 7th, 14th, and 28th post bleomycin administration, and lungs were removed respectively. For histological evaluation of lungs injury and fibrosis, lung specimens were stained with hematoxylin and eosin (HE) and Masson trichrome. Body weight and lung index from various groups were measured, and the concentrations of monoamine (MAO) and transforming growth factor-β1(TGF-β1) were also detected in lung homogenates. Results: SGYC attenuated the bleomycin-induced weight loss and the lung index. Histologica levidence showed the ability of SGYC to decrease bleomycin-induced lung fibrosis and consolidation. SGYC reduced the MAO and TGF-β1 activityin lung tissues. Conclusions: These findings suggest that SGYC may be a promising candidate to prevent bleomycin-induced lung damage or other interstitial lesions.
